Insulin-like growth factor-II
Alternative Names: Somatomedin-2Latest Information Update: 21 Aug 2007
At a glance
- Originator Eli Lilly and Company; KabiGen; Karolinska Institute
- Class Antihyperglycaemics; Antineoplastics; Growth factors; Peptides
- Mechanism of Action Insulin-like growth factor II stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 08 Oct 2001 No-Development-Reported for Diabetes mellitus (Unknown route)
- 06 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
- 13 Oct 1995 Eli Lilly is developing somatomedin-2 in the USA